Earol Madrid Study (EMS)

Multi-center, Open-label, Non-randomized, Single-arm Clinical Study to Assess the Safety and Performance of Earol® in Adult Patients With Ear Wax

Accumulation of ear wax in the external ear canal is a common pathology. The presence of ear wax not only interferes with the clinician's view of the tympanic membrane, but may also result in hearing loss and vertigo, and may predispose to ear infections.

Removal of ear wax is facilitated using a variety of cerumenolytics, or ear wax solvents. The current study is designed to evaluate the safety and the cerumenolytic effects of the Earol product, when dosed into the auditory canal prior to the dewaxing and ear cleaning procedure. This study is designed to be conducted in the primary care setting as a prospective clinical trial.

A detailed literature review has been conducted to provide a background summary of relevant information on the disease/pathology, other available treatment options and the pre-clinical testing and clinical research that has been conducted to date on the intended population or related populations and/or the device.

The aim for conducting this clinical investigation is to perform a PMCF to evaluate the safety and performance of Earol. Although there are alternative methods for ear wax removal, Earol represents a simple method based on natural ingredients (olive oil) which aids the removal of ear wax as well as prevents appearance of clinical symptoms in the ear canal (E.g. reducing itching and irritation).

Study Overview

• Status: Completed
• Conditions: Cerumen Impaction of Both Ears
• Intervention / Treatment: Device: Earol

• Study Type: Interventional
• Enrollment (Actual): 108
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Madrid, Spain
    • Clinica Universidad de Navarra
  • Madrid, Spain
    • Hospital Universitario de Getafe
  • Madrid, Spain
    • Hospital Quirónsalud Madrid
  • Marbella, Spain
    • Hospital Quirónsalud Marbella
  • Sevilla, Spain
    • Hospital Quironsalud Infanta Luisa

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject must be willing to provide written informed consent prior to any clinical investigation related procedure;
• Male or female patients over 18-year-old;
• Presence of ear wax in both ear canals with a minimum of > 50% ear wax blockage in at least one ear (level 4) and > 25% blockage in the contralateral ear (level 3) as assessed using the TMVSS;
• Subject must be willing and able to perform all the visits, follow the PI instructions and complete the follow-up of the study.

Exclusion Criteria:

• Subject is currently participating in another clinical investigation or has participated in another clinical investigation in the past 30 days prior to the start of the present study;
• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period;
• Presence of other anatomic or comorbid conditions (e.g. ear eczema or seborrhea), or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness;
• Presence or history of a tympanic membrane perforation or tympanostomy tubes at any time during the previous 6 months;
• Presence or history of a known or suspected ear infection (i.e. otitis externa or otitis interna) in the previous 2 months;
• Presence of a known or suspected chronic suppurative otitis media;
• Presence or history of a known or suspected keratosis obturans;
• Presence of known or suspected mastoiditis;
• Use of any ototopical drug or OTC product or ear wax-removal product (except for water or physiologic saline) during the preceding 3 days;
• Hypersensitivity to any product ingredient(s) or history of anaphylactic/anaphylactoid reactions;
• Temporal bone neoplasm.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment group; Treatment group arm. Open label. Only 1 arm study	Device: Earol; Treated with Earol on both ears and subsequent removal after 6 days of application; Other Names: Ear Wax removal

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SAEs and AEs reported	Adverse Events (AEs) and Serious Adverse Events (SAEs) post-treatment	Day 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cerumen blockage assesment	Visualization of the tympanic membrane where cerumen blockage will be assessed post-treatment through the literature and protocol described tool TMVSS (Tympanic Membrane Visualization Scoring System). This scale measures the level of obstruction of the ear canal by assessing the level of obstruction when trying to visualize the tympanic membrane with an otoscope. Level of obstruction 1 - < 3 % Level of obstruction 2 - 3 - 25 % Level of obstruction 3 - 26 - 50 % Level of obstruction 4 - 51 - 75 % Level of obstruction 5 - 76 - 100 %	Day 0 and Day 6
Ear clinical symptoms	Evaluate ear-specific clinical symptoms (e.g. dryness and itchiness) through a MD questionnaire. This scale has been specifically developed for this clinical trial. - Clinical symptoms questionnaire (MD): Incidence of clinical symptoms and assessment scale of the intensity and frequency of the clinical symptoms (itchiness and dryness).	Day 0 and Day 6
Patient clinical symptoms	Patient Questionnaire collecting clinical symptom prior and post-treatment This scale has been specifically developed for this clinical trial. - Clinical symptoms questionnaire (patient): Incidence of clinical symptoms and assessment scale of the intensity and frequency of the clinical symptoms (itchiness and dryness).	Day 0 and Day 6
SAEs and AEs reported	Adverse Events (AEs) and Serious Adverse Events (SAEs) post-treatment.	Day 12
Patient clinical symptom and ease-of-use	Patient Questionnaire assessing the ease-of-use of the medical device (Earol). This scale has been specifically developed for this clinical trial. - Ease of use of the device questionnaire: rating scale 0 - 10	Day 6

Collaborators and Investigators

• Sponsor: HL Healthcare Ltd
• Collaborators: AKRN Scientific Consulting, S.L.

Study record dates

Study Major Dates

• Study Start (Actual): December 3, 2019
• Primary Completion (Actual): June 17, 2021
• Study Completion (Actual): January 26, 2022

Study Registration Dates

• First Submitted: November 16, 2020
• First Submitted That Met QC Criteria: November 30, 2020
• First Posted (Actual): December 4, 2020

Study Record Updates

• Last Update Posted (Actual): March 20, 2023
• Last Update Submitted That Met QC Criteria: March 17, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: Olive oil; Ear Wax Removal; Ear Wax; Earol; Cerumen; Impaction
• Additional Relevant MeSH Terms: Anti-Infective Agents, Local; Anti-Infective Agents; Carbamide Peroxide
• Other Study ID Numbers: CD1620-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No